UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D. C. 20549

FORM 10-Q

(Mark One)

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2023

OR

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from            to          

NORTECH SYSTEMS INCORPORATED

Commission file number 0-13257

State of Incorporation: Minnesota

IRS Employer Identification No. 41-1681094

Executive Offices:  7550 Meridian Circle N., Suite #150, Maple Grove, MN 55369

Telephone number: (952) 345-2244

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value $.01 per share	NSYS	NASDAQ Capital Market

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days . Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulations S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).  Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large Accelerated Filer ☐	Accelerated Filer ☐
Non-accelerated Filer ☒	Smaller Reporting Company ☒
Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐    

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  Yes ☐ No ☒

Number of shares of $.01 par value common stock outstanding at May 5, 2023 was 2,700,633.

1

TABLE OF CONTENTS

PART I - FINANCIAL INFORMATION
	PAGE
Item 1    -    Financial Statements
Condensed Consolidated Statements of Operations and Comprehensive Income	3
Condensed Consolidated Balance Sheets	4
Condensed Consolidated Statements of Cash Flows	5
Condensed Consolidated Statements of Shareholders’ Equity	7
Condensed Notes to Consolidated Financial Statements	8-19
Item 2    -    Management's Discussion and Analysis of Financial Condition And Results of Operations	20-25
Item 3    -    Quantitative and Qualitative Disclosures About Market Risk	26
Item 4    -    Controls and Procedures	26
PART II - OTHER INFORMATION
Item 1    -    Legal Proceedings	27
Item 1A.-    Risk Factors	27
Item 2    -    Unregistered Sales of Equity Securities, Use of Proceeds	27
Item 3    -    Defaults on Senior Securities	27
Item 4    -    Mine Safety Disclosures	27
Item 5    -    Other Information	27
Item 6    -    Exhibits	28
SIGNATURES	29

2

PART

ITEM 1. FINANCIAL STATEMENTS

NORTECH SYSTEMS INCORPORATED AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME

(UNAUDITED)

(IN THOUSANDS, EXCEPT SHARE DATA)

	THREE MONTHS ENDED
	MARCH 31,
	2023			2022
Net Sales	$	34,888		$	30,711
Cost of Goods Sold		29,404			26,667
Gross Profit		5,484			4,044
Operating Expenses
Selling Expenses		890			833
General and Administrative Expenses		3,265			2,729
Research and Development Expenses		276			328
Gain on Sale of Assets		-			(15	)
Total Operating Expenses		4,431			3,875
Income From Operations		1,053			169
Other Expense
Interest Expense		(110	)		(98	)
Income Before Income Taxes		943			71
Income Tax Expense (Benefit)		262			(67	)
Net Income	$	681		$	138
Net Income Per Common Share:
Basic (in dollars per share)	$	0.25		$	0.05
Weighted Average Number of Common Shares Outstanding - Basic (in shares)		2,692,033			2,680,731
Diluted (in dollars per share)	$	0.23		$	0.05
Weighted Average Number of Common Shares Outstanding - Diluted (in shares)		2,903,635			2,871,901
Other comprehensive income
Foreign currency translation		40			5
Comprehensive income, net of tax	$	721		$	143

See Accompanying Condensed Notes to Condensed Consolidated Financial Statements

3

NORTECH SYSTEMS INCORPORATED AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(IN THOUSANDS, EXCEPT SHARE DATA)

	MARCH 31,			DECEMBER 31,
	2023			2022(1)
	(Unaudited)
ASSETS
Current Assets
Cash	$	1,267		$	1,027
Restricted Cash		1,366			1,454
Accounts Receivable, less allowances of $303 and $334		16,219			15,975
Employee Retention Credit Receivable		2,650			2,650
Inventories, Net		21,344			22,438
Contract Assets, less allowances of $20 and $0		10,790			9,982
Prepaid Expenses		1,933			1,334
Total Current Assets		55,569			54,860
Property and Equipment, Net		6,543			6,408
Operating Lease Assets		7,561			7,850
Other Intangible Assets, Net		382			422
Total Assets	$	70,055		$	69,540
LIABILITIES AND SHAREHOLDERS' EQUITY
Current Liabilities
Current Portion of Finance Lease Obligations	$	394		$	390
Current Portion of Operating Lease Obligations		1,130			1,155
Accounts Payable		13,082			14,792
Accrued Payroll and Commissions		6,048			4,803
Income Taxes Payable		837			733
Customer Deposits		4,830			3,515
Other Accrued Liabilities		1,128			1,010
Total Current Liabilities		27,449			26,398
Long-Term Liabilities
Long Term Line of Credit		5,845			6,853
Long Term Finance Lease Obligations, Net		465			565
Long-Term Operating Lease Obligations, Net		7,297			7,549
Other Long-Term Liabilities		94			95
Total Long-Term Liabilities		13,701			15,062
Total Liabilities		41,150			41,460
Commitments and Contingencies
Shareholders' Equity
Preferred Stock, $1 par value; 1,000,000 Shares Authorized: 250,000 Shares Issued and Outstanding		250			250
Common Stock - $0.01 par value; 9,000,000 Shares Authorized: 2,700,633 and 2,690,633 Shares Issued and Outstanding, respectively		27			27
Additional Paid-In Capital		16,481			16,347
Accumulated Other Comprehensive Loss		(330	)		(370	)
Retained Earnings		12,477			11,826
Total Shareholders' Equity		28,905			28,080
Total Liabilities and Shareholders' Equity	$	70,055		$	69,540

See Accompanying Condensed Notes to Condensed Consolidated Financial Statements

⁽¹⁾ The balance sheet at December 31, 2022 has been derived from the audited financial statements at that date

4

NORTECH SYSTEMS INCORPORATED AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)

(IN THOUSANDS)

	THREE MONTHS ENDED
	MARCH 31,
	2023			2022
CASH FLOWS PROVIDED BY OPERATING ACTIVITIES
Net Income	$	681		$	138
Adjustments to Reconcile Net Income to Net Cash Provided By Operating Activities:
Depreciation and Amortization		505			486
Compensation on Stock-Based Awards		99			48
Change in Inventory Reserves		32			97
Other, Net		(47	)		23
Changes in Current Operating Items
Accounts Receivable		(206	)		(188	)
Inventories		1,075			(1,852	)
Contract Assets		(823	)		585
Prepaid Expenses and other Curent Assets		(600	)		(263	)
Income Taxes		113			(168	)
Accounts Payable		(1,799	)		1,302
Accrued Payroll and Commissions		1,244			845
Customer Deposits		1,315			456
Other Accrued Liabilities		129			(18	)
Net Cash Provided By Operating Activities		1,718			1,491
CASH FLOWS FROM INVESTING ACTIVITIES
Proceeds from Sale of Property and Equipment		-			15
Purchases of Property and Equipment		(496	)		(529	)
Net Cash Used In Investing Activities		(496	)		(514	)
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from Line of Credit		31,133			26,986
Payments to Line of Credit		(32,145	)		(28,420	)
Principal Payments on Financing Leases		(96	)		(184	)
Stock Option Excercises		35			33
Net Cash Used In Financing Activities		(1,073	)		(1,585	)
Effect of Exchange Rate Changes on Cash		3			-
Net Change in Cash and Cash Equivalents		152			(608	)
Cash and Cash Equivalents - Beginning of Year		2,481			2,225
Cash and Cash Equivalents - End of Year	$	2,633		$	1,617
Reconciliation of cash and restricted cash reported within the consolidated balance sheets
Cash	$	1,267		$	841
Restricted Cash		1,366			776
Total Cash and restricted cash reported in the consolidated statements of cash flows	$	2,633		$	1,617

5

NORTECH SYSTEMS INCORPORATED AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)

(IN THOUSANDS)

	THREE MONTHS ENDED
	MARCH 31,
	2023		2022
Supplemental Disclosure of Cash Flow Information:
Cash Paid During the Period for Interest	$	129	$	94
Cash Paid During the Period for Income Taxes		112		-
Supplemental Noncash Investing and Financing Activities:
Property and Equipment Purchases in Accounts Payable		78		-

See Accompanying Condensed Notes to Condensed Consolidated Financial Statements

6

NORTECH SYSTEMS INCORPORATED AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY

(UNAUDITED)

(IN THOUSANDS)

							Accumulated
					Additional		Other						Total
	Preferred		Common		Paid-In		Comprehensive			Retained			Shareholders'
	Stock		Stock		Capital		Income (Loss)			Earnings			Equity
BALANCE DECEMBER 31, 2021	$	250	$	27	$	15,962	$	56		$	9,816		$	26,111
Net Income		-		-		-		-			138			138
Foreign currency translation adjustment		-		-		-		5			-			5
Stock option exercises		-		-		33		-			-			33
Compensation on stock-based awards		-		-		48		-			-			48
BALANCE MARCH 31, 2022	$	250	$	27	$	16,043	$	61		$	9,954		$	26,335
BALANCE DECEMBER 31, 2022	$	250	$	27	$	16,347	$	(370	)	$	11,826		$	28,080
Net Income		-		-		-		-			681			681
Foreign currency translation adjustment		-		-		-		40			-			40
Stock option exercises		-		-		35		-			-			35
Compensation on stock-based awards		-		-		99		-			-			99
Cumulative adjustment related to the adoption of ASC 326		-		-		-		-			(30	)		(30	)
BALANCE MARCH 31, 2023	$	250	$	27	$	16,481	$	(330	)	$	12,477		$	28,905

See Accompanying Condensed Notes to Condensed Consolidated Financial Statements

7

CONDENSED NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(DOLLARS IN THOUSANDS, EXCEPT SHARE AND PER SHARE DATA)
(UNAUDITED)

NOTE 1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

The accompanying unaudited condensed consolidated financial statements for the interim periods have been prepared in accordance with Generally Accepted Accounting Principles in the United States of America (“GAAP”) for interim financial information and pursuant to the rules and regulations of the Securities and Exchange Commission. Accordingly, they do not include all of the financial information and footnotes required by GAAP for complete financial statements, although we believe the disclosures are adequate to make the information presented not misleading. It is suggested that these condensed consolidated financial statements be read in conjunction with the consolidated financial statements and the notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2022. The operating results for the interim periods presented are not necessarily indicative of the results expected for the full year or for any other interim period. In our opinion, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included.

The preparation of financial statements in conformity with GAAP requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. In preparing these condensed consolidated financial statements, we have made our best estimates and judgments of certain amounts included in the condensed consolidated financial statements, giving due consideration to materiality. Changes in the estimates and assumptions used by us could have a significant impact on our financial results, since actual results could differ from those estimates.

Principles of Consolidation

The condensed consolidated financial statements include the accounts of Nortech Systems Incorporated and its wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated.

Revenue Recognition

Our revenue is comprised of product, engineering services and repair services. All revenue is recognized when the Company satisfies its performance obligation(s) under the contract by transferring the promised product or service to our customer either when (or as) our customer obtains control of the product or service, with the majority of our revenue being recognized over time including goods produced under contract manufacturing agreements and services revenue. A performance obligation is a promise in a contract to transfer a distinct product or service to a customer. A contract’s transaction price is allocated to each distinct performance obligation. The majority of our contracts have a single performance obligation. Revenue is recorded net of returns, allowances and customer discounts. Our net sales for services were less than 10% of our total sales for all periods presented, and accordingly, are included in net sales in the Condensed Consolidated Statements of Operations and Comprehensive Income. Sales, value add, and other taxes collected from customers and remitted to governmental authorities are accounted for on a net (excluded from revenues) basis. Shipping and handling costs charged to our customers are included in net sales, while the corresponding shipping expenses are included in cost of goods sold.

8

Stock-Based Awards

Stock Options

In May 2017, the shareholders approved the 2017 Stock Incentive Plan which authorized the issuance of 350,000 shares. An additional 50,000 and 175,000 shares were authorized by the shareholders in March 2020 and May 2022, respectively.

There were no service-based or market-based stock options granted during the three months ended March 31, 2023. There was 53,000 service-based and 21,000 market-based stock options granted during the three months ended March 31, 2022.The market condition options vest if certain stock prices are exceeded between February 27, 2024 and February 27, 2028.

Total compensation expense related to stock options was $68 and $43 for the three months ended March 31, 2023 and 2022, respectively. As of March 31, 2023, there was $694 of unrecognized compensation which will vest over the next 3.45 years.

Following is the status of all stock options as of March 31, 2023:

	Shares			Weighted- Average Exercise Price Per Share		Weighted- Average Remaining Contractual Term (in years)		Aggregate Intrinsic Value (in thousands)
Outstanding - January 1, 2023		452,700		$	5.97
Granted		-			-
Exercised		(10,000	)		3.43
Cancelled		(1,600	)		7.18
Outstanding - March 31, 2023		441,100		$	6.02		6.68	$	2,100
Exercisable - March 31, 2023		247,700		$	4.38		5.72	$	1,556

Restricted Stock Units

During the three months ended March 31, 2022, we granted 21,000 restricted stock units (“RSUs”) under our 2017 Stock Incentive Plan to non-employee directors which vest over two years. There were no RSUs granted for the three months ended March 31, 2023. Total compensation expense related to the RSUs was $31 and $5 for the three months ended March 31, 2023 and 2022, respectively. Total unrecognized compensation expense related to the RSUs was $124, which will vest over the next 12 months. 9,000 RSUs vested during the three months ended March 31, 2023 but were not yet transferred to the directors as of March 31, 2023.

Net Income per Common Share

Basic net income per common share is computed by dividing net income by the weighted-average number of common shares outstanding. Dilutive net income per common share assumes the exercise and issuance of all potential common stock equivalents in computing the weighted-average number of common shares outstanding, unless their effect is antidilutive. All stock options and restricted stock units, while outstanding, are considered common stock equivalents. For the three months ended March 31, 2023 and 2022, stock options of 211,602 and 191,170, respectively, were included in the computation for diluted income per common share as their impact were dilutive.

9

We had outstanding stock options totaling 20,518 and RSUs totaling 8,118 that are not included in the computation of diluted net income per share as their effect would have been anti-dilutive for the three months ended March 31, 2023.

Restricted Cash

Cash and cash equivalents classified as restricted cash on our consolidated balance sheets are restricted as to withdrawal or use under the terms of certain contractual agreements. As of March 31, 2023, we had outstanding letters of credit for $300. Restricted cash as of March 31, 2023 was $1,366. The March 31, 2023 and December 31, 2022 restricted cash balance included lockbox deposits that are temporarily restricted due to timing at the period end. The lockbox deposits are applied against our line of credit the next business day.

Accounts Receivable

Credit is extended based upon an evaluation of the customer’s financial condition and, while collateral is not required, the Company periodically receives surety bonds that guarantee payment. Credit terms are consistent with industry standards and practices.

Allowance for Credit Losses

When we record customer receivables and contract assets arising from revenue transactions, we record an allowance for credit losses for the current expected credit losses (CECL) inherent in the asset over its expected life. The allowance for credit losses is a valuation account deducted from the cost basis of the assets to present their net carrying value at the amount expected to be collected. Each period, the allowance for credit losses is adjusted through earnings to reflect expected credit losses over the remaining lives of the assets.

We estimate expected credit losses based on relevant information about past events, including historical experience, current conditions, and reasonable and supportable forecasts that affect the collectability of the reported amount. When measuring expected credit losses, we pool assets with similar country risk and credit risk characteristics. Changes in the relevant information may significantly affect the estimates of expected credit losses.

Assets are written off when we determine them to be uncollectible. Write-offs are recognized as a deduction from the allowance for credit losses.

Inventories

Inventories are stated at the lower of average cost (which approximates first-in, first out) or net realizable value. Costs include material, labor, and overhead required in the warehousing and production of our products. Inventory reserves are maintained for the estimated value of the inventories that may have a lower value than stated or quantities in excess of future production needs.

10

Inventories are as follows:

	March 31,			December 31,
	2023			2022
Raw Materials	$	20,983		$	21,673
Work in Process		865			1,238
Finished Goods		672			671
Reserves		(1,176	)		(1,144	)
Total	$	21,344		$	22,438

Other Intangible Assets

Other intangible assets at March 31, 2023 and December 31, 2022 are as follows:

	Customer Relationships		Patents		Total
Balance at January 1, 2022	$	360	$	141	$	501
Additions		-		71		71
Amortization		144		6		150
Balance at December 31, 2022		216		206		422
Amortization		36		4		40
Balance at March 31, 2023	$	180	$	202	$	382

Intangible assets are amortized on a straight-line basis over their estimated useful lives. The weighted-average remaining amortization period of our intangible assets is 1.6 years. Of the patents value at March 31, 2023, $95 are being amortized and $111 are in process and a patent has not yet been received.

Amortization expense of finite life intangible assets for the three months ended March 31, 2023 and 2022 was $40 and $36, respectively.

Estimated future annual amortization expense (not including patents in process of $111) related to these assets is approximately as follows:

Year	Amount
Remainder of 2023	$	119
2024		87
2025		14
2026		14
Thereafter		37
Total	$	271

11

Adoption of New Accounting Standards

In June 2016, the FASB issued ASU 2016-13, Financial Instruments – Credit Losses (Topic 326). The ASU introduces a new credit loss methodology, Current Expected Credit Losses (CECL), which requires earlier recognition of credit losses, while also providing additional transparency about credit risk.

The CECL methodology utilizes a lifetime “expected credit loss” measurement objective for the recognition of credit losses for loans, held-to-maturity securities and other receivables at the time the financial asses is originated or acquired. The expected credit losses are adjusted each period for changes in expected lifetime credit losses. The methodology replaces the multiple existing impairment methods in current GAAP, which generally require that a loss be incurred before it is recognized.

On January 1, 2023, we adopted the guidance prospectively with a cumulative adjustment to retained earnings. We have not restated comparative information for 2022 and, therefore, the comparative information for 2022 is reported under the old model and is not comparable to the information presented for 2023.

At adoption, we recognized an allowance for credit losses related to accounts receivable and contract assets of $30, net of tax, and a decrease in retained earnings of $30 associated with the increased estimated credit losses.

Revision and Immaterial Correction of an Error in Previously Issued Financial Statements

The Company identified an error related to the classification of the activity on our line of credit facility with Bank of America at December 31, 2022 as reported on Form 10-K. In our March 31, 2022 condensed consolidated financial statements, we incorrectly classified borrowings and payments on our line of credit facility on a net basis within the financing section of the condensed consolidated cash flow statement; this activity should be shown on a gross basis. This change in presentation to the condensed consolidated cash flow statement does not impact total operating, investing, or financing cash flows. There was no change to the condensed consolidated statement of income or condensed consolidated balance sheet. In accordance with ASC 250, Accounting Changes and Error Corrections, we evaluated the materiality of the errors from quantitative and qualitative perspectives and concluded that the errors were immaterial to the Company’s 2022 audited financial statements. Since these revisions were not material to any prior period financial statements, no amendments to previously filed financial statements are required. Consequently, the Company has corrected these immaterial errors by revising the March 31, 2022 consolidated financial statements presented herein.

12

The tables below present the effect of the financial statement adjustments related to the revision discussed above of the Company’s previously reported financial statements as of and for the period ended March 31, 2022:

Condensed Consolidated Statements of Cash Flows
	March 31, 2022
CASH FLOWS FROM FINANCING ACTIVITIES	As reported			Adjustment			As revised
Net Proceeds from Line of Credit		(1,434	)		1,434			-
Proceeds from Line of Credit		-			26,986			26,986
Payments to Line of Credit		-			(28,420	)		(28,420	)
Principal Payments on Long-Term Debt		-						-
Principal Payments on Financing Leases		(184	)					(184	)
Stock Option Exercises		33						33
Net Cash Provided by Financing Activities		(1,585	)		-			(1,585	)

NOTE 2. CONCENTRATION OF CREDIT RISK AND MAJOR CUSTOMERS

Financial instruments that potentially subject us to concentrations of credit risk consist principally of cash, accounts receivable, and contract asset. With regard to cash, we maintain our excess cash balances in checking accounts at primarily two financial institutions, one in the United States and one in China. The account in the United States may at times exceed federally insured limits. Of the $2,633 in cash and restricted cash at March 31, 2023, approximately $1,229 and $13 was held at banks located in China and Mexico, respectively. We grant credit to customers in the normal course of business and do not require collateral on our accounts receivable.

We have certain customers whose revenue individually represented 10% or more of net sales, whose accounts receivable balances individually represented 10% or more of gross accounts receivable, or whose contract asset balances individually represetend 10% or more of contract assets. One customer accounted for 29% and 23% of net sales for the three months ended March 31, 2023 and 2022, respectively. Accounts receivable for one customer accounted for 24% and 21% of gross accounts receivable at March 31, 2023 and December 31, 2022, respectively. Contract assets for one customer accounted for 20% and 22% of gross contract assets at March 31, 2023 and December 31, 2022, respectively.

Export sales represented approximately 4% and 5% of net sales for the three months ended March 31, 2023 and 2022, respectively.

13

NOTE 3. REVENUE

Revenue recognition

Our revenue is comprised of product, engineering services and repair services. All revenue is recognized when the Company satisfies its performance obligation(s) under the contract by transferring the promised product or service to our customer either when (or as) our customer obtains control of the product or service, with the majority of our revenue being recognized over time including goods produced under contract manufacturing agreements and services revenue. A performance obligation is a promise in a contract to transfer a distinct product or service to a customer. A contract’s transaction price is allocated to each distinct performance obligation. The majority of our contracts have a single performance obligation, as the promise to transfer products or services is not separately identifiable from other promises in the contract and, therefore, not distinct.

Revenue is measured as the amount of consideration we expect to receive in exchange for transferring products or providing services. As such, revenue is recorded net of returns, allowances and customer discounts. Sales, value add, and other taxes collected from customers and remitted to governmental authorities are accounted for on a net (excluded from revenues) basis. Shipping and handling costs are included in cost of goods sold.

The majority of our revenue is derived from the transfer of goods produced under contract manufacturing agreements which have no alternative use and we have an enforceable right to payment for our performance completed to date. Our performance obligations within our contract manufacturing agreements are generally satisfied over time as the goods are produced based on customer specifications and we have an enforceable right to payment for the goods produced. Revenues under these agreements are generally recognized over time using an input measure based upon the proportion of actual costs incurred. If these requirements are not met, the revenue is recognized at a point in time, generally upon shipment. Revenue under contract manufacturing agreements that was recognized over time accounted for approximately 74% and 73% of our revenue for the three months ended March 31, 2023 and 2022, respectively.

Accounting for contract manufacturing agreements involves the use of various techniques to estimate total revenue and costs. We estimate profit on these agreements as the difference between total estimated revenue and expected costs to complete the performance obligation within the terms of the agreement and recognize the respective profit as the goods are produced. The estimates to determine the profit earned on the performance obligation are based on anticipated selling prices and historical cost of goods sold and represent our best judgement at the time. Changes in judgements on these above estimates could impact the timing and amount of revenue recognized with a resulting impact on the timing and amount of associated profit.

On occasion our customers provide materials to be used in the manufacturing process and the fair value of the materials is included in revenue as noncash consideration at the point in time when the manufacturing process commences along with the same corresponding amount recorded as cost of goods sold. The inclusion of noncash consideration has no impact on overall profitability.

14

Contract Assets

Contract assets, recorded as such in the Consolidated Balance Sheet, consist of unbilled amounts related to revenue recognized over time. Significant changes in the contract assets balance during the three months ended March 31, 2023 was as follows (in thousands):

Balance outstanding at December 31, 2022	$	9,982
Increase (decrease) attributed to:
Amounts transferred over time to contract assets		25,730
Allowance for current expected credit losses		(20	)
Amounts invoiced during the period		(24,902	)
Balance outstanding at March 31, 2023	$	10,790

We expect substantially all of the remaining performance obligations for the contract assets recorded as of March 31, 2023, to be transferred to receivables within 90 days, with any remaining amounts to be transferred within 180 days. We bill our customers upon shipment with payment terms of up to 120 days.

The following tables summarize our net sales by market for the three ended March 31, 2023 and 2022, respectively:

	Three Months Ended March 31, 2023
	Product/ Service Transferred Over Time		Product Transferred at Point in Time		Noncash Consideration		Total Net Sales by Market
Medical	$	15,725	$	5,061	$	586	$	21,372
Industrial		6,590		2,408		474		9,472
Aerospace and Defense		3,415		550		79		4,044
Total net sales	$	25,730	$	8,019	$	1,139	$	34,888

	Three Months Ended March 31, 2022
	Product/ Service Transferred Over Time		Product Transferred at Point in Time		Noncash Consideration		Total Net Sales by Market
Medical	$	9,807	$	4,915	$	544	$	15,266
Industrial		6,529		1,791		347		8,667
Aerospace and Defense		6,057		425		296		6,778
Total net sales	$	22,393	$	7,131	$	1,187	$	30,711

15

NOTE 4. FINANCING ARRANGEMENTS

We have a credit agreement with Bank of America, which was entered into on June 15, 2017 and provides for a line of credit arrangement of $16,000 that expires on June 15, 2026.

Under the amended Bank of America credit agreement signed December 31, 2021, the line of credit is subject to variations in the Bloomberg Short-Term Bank Yield (BSBY) index rate. Our line of credit bears interest at a weighted-average interest rate of 7.3% and 5.2% as of March 31, 2023 and December 31, 2022, respectively. We had borrowings on our line of credit of $5,886 and $6,897 outstanding as of March 31, 2023 and December 31, 2022, respectively. There are no subjective acceleration clauses under the credit agreement that would accelerate the maturity of our outstanding borrowings. In addition, the credit agreement does not expire within one year, the Company is not in violation of the covenants and the Company expects Bank of America to be capable of honoring the financing arrangement. The line of credit is shown net of debt issuance costs of $41 and $44 on the condensed consolidated balance sheet for the periods ended March 31, 2023 and December 31, 2022, respectively.

The line of credit with Bank of America contains certain covenants which, among other things, require us to adhere to regular reporting requirements, abide by annual shareholder dividend limitations, maintain certain financial performance, and limit the amount of annual capital expenditures.

The Bank of America Credit Agreement provides for, among other things, a Fixed Charge Coverage Ratio of not less than 1.0 to 1.0, for the twelve months ending December 31, 2020 and each Fiscal Quarter end thereafter subject only during a trigger period commencing when our availability under our line is less than $2,000 until availability is above that amount for 30 days. The Company met the covenants for the period ended March 31, 2023.

At March 31, 2023, we had unused availability under our line of credit of $5,934 supported by our borrowing base. The line is secured by substantially all of our assets.

NOTE 5. LEASES

We have operating leases for certain manufacturing sites, office space, and equipment. Most leases include the option to renew, with renewal terms that can extend the lease term from one to five years or more. Right-of-use lease assets and lease liabilities are recognized at the commencement date based on the present value of the remaining lease payments over the lease term which includes renewal periods we are reasonably certain to exercise. Our leases do not contain any material residual value guarantees or material restrictive covenants. At March 31, 2023, we do not have material lease commitments that have not commenced.

The components of lease expense were as follows:

	March 31,		March 31,
Lease Cost	2023		2022
Operating lease cost	$	567	$	581
Finance lease interest cost		12		19
Finance lease amortization expense		182		182
Total lease cost	$	761	$	782

16

Supplemental balance sheet information related to leases was as follows:

	Balance Sheet Location	March 31, 2023		December 31, 2022
Assets
Operating lease assets	Operating lease assets	$	7,561	$	7,850
Finance lease assets	Property, Plant and Equipment		1,181		1,363
Total leased assets		$	8,742	$	9,213

Supplemental cash flow information related to leases was as follows:

	March 31,		March 31,
	2023		2022
Operating leases
Cash paid for amounts included in the measurement of lease liabilities	$	493	$	434

Maturities of lease liabilities were as follows:

	Operating Leases			Finance Leases			Total
Remaining 2023	$	1,343		$	325		$	1,668
2024		1,516			379			1,895
2025		1,265			103			1,368
2026		1,227			109			1,336
2027		1,256			-			1,256
Therafter		5,818			-			5,818
Total lease payments	$	12,425		$	916		$	13,341
Less: Interest		(3,998	)		(57	)		(4,055	)
Present value of lease liabilities	$	8,427		$	859		$	9,286

The lease term and discount rate at March 31, 2023 were as follows:

Weighted-average remaining lease term (years)
Operating leases	8.8
Finance leases	2.4
Weighted-average discount rate
Operating leases	7.7	%
Finance leases	5.2	%

17

NOTE 6. INCOME TAXES

On a quarterly basis, we estimate what our effective tax rate will be for the full fiscal year and record a quarterly income tax provision based on the anticipated rate. As the year progresses, we refine our estimate based on the facts and circumstances, including discrete events, by each tax jurisdiction. Our effective tax rate for the three months ended March 31, 2023 and 2022 was 28% and (94)%, respectively. The primary drivers of the change in the effective tax rate relates to an increase in the valuation allowance on United States deferred tax assets and taxes on foreign entities.The prior year income tax benefit was attributable to the US loss compared to book income on foreign entities and expected US book income for the year.

NOTE 7. EMPLOYEE RETENTION CREDIT

On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”) was signed into law providing numerous tax provisions and other stimulus measures, including an employee retention credit (“ERC”), which is a refundable tax credit against certain employment taxes. The Taxpayer Certainty and Disaster Tax Relief Act of 2020 and the American Rescue Plan Act of 2021 extended and expanded the availability of the ERC.

During the year ended December 31, 2022, we received payment on the Employee Retention Credit for the first quarter of 2021 of $2,559. At March 31, 2023 and December 31, 2022, the Company has ERC benefits of $2,650 within Employee Retention Credits Receivable on the condensed consolidated balance sheet. The company received payment on this remaining receivable on May 1, 2023.

18

NOTE 8. RELATED PARTY TRANSACTIONS

David Kunin, our Chairman, is a minority owner of Abilitech Medical, Inc. Mr. Kunin also was a consultant to Abilitech through March 1, 2021. In the three months ended March 31, 2023 and 2022, Abilitech paid the Company $0 and $54, respectively, for delivery of medical products. We have assets recorded related to Abilitech including $226 of accounts receivable and inventory. We do not believe that Abilitech will pay the Company for outstanding accounts receivable or for inventory and we have recorded a full reserve against the gross amounts. The Company believes that transactions with Abilitech are on terms comparable to those that the Company could reasonably expect in an arm's length transaction with an unrelated third party.

David Kunin, our Chairman, is a minority owner (less than 10%) of Marpe Technologies, LTD an early-stage medical device company dedicated to the early detection of skin cancer through full body scanners. Mr. Kunin is also a member of the Board of Directors of Marpe Technologies. The Company worked with Marpe Technologies to apply for a grant from the Israel-United States Binational Industrial Research and Development Foundation, a legal entity created by Agreement between the Government of the State of Israel and the Government of the United States of America (“BIRD Foundation”). The parties were successful in receiving approval for a $1,000 conditional grant. The Company and Marpe Technologies will each receive $500 from the BIRD Foundation and, among other obligations under the grant, each is required to contribute $500 to match grant funds from the BIRD Foundation. The Company will meet its obligation by providing certain services at cost or with respect to administrative services at no cost to Marpe Technologies. The total value of the Company’s contribution will not exceed $500. Marpe is engaged in raising funds for its operations, which funds are necessary to pay for the Company’s services beyond its contribution. The Company will receive a 10-year exclusive right to manufacture the products of Marpe Technologies. There can be no assurances that Marpe Technologies’ medical device operations will be commercially successful, that Marpe Technologies will be successful in raising additional funds to finance its operations or, if commercially successful, the Company will recover the value of services provided to Marpe if not paid when the services are provided. The transactions between the Company and Marpe Technologies have been approved by the Audit Committee pursuant to the Company Related-Party Transactions Policy. During the three months ended March 31, 2023 and 2022, we recognized revenue of providing services to Marpe Technologies of $67 and $169, respectively. The Company believes that transactions with Marpe are on terms comparable to those that the Company could reasonably expect in an arm’s length transaction with an unrelated third party.

19

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Overview

We are a Minnesota, United States based full-service global EMS contract manufacturer in the Medical, Aerospace & Defense and Industrial markets offering a full range of value-added engineering, technical and manufacturing services and support including project management, design, testing, prototyping, manufacturing, supply chain management and post-market services. Our products are complex electromedical and electromechanical products including medical devices, wire and cable assemblies, printed circuit board assemblies, higher-level assemblies, and other box builds for a wide range of industries. We serve three major markets within the EMS industry: Aerospace and Defense, Medical, and the Industrial market, which includes industrial capital equipment, transportation, vision, agriculture, oil and gas. We maintain facilities in Bemidji, Blue Earth, Mankato, and Milaca, Minnesota; Monterrey, Mexico; and Suzhou, China. All of our facilities are certified to one or more of the ISO/AS standards, including 9001, AS9100 and 13485, with most having additional certifications based on the needs of the customers they serve.

Results of Operations

The following table presents statements of operations data as percentages of total net sales for the periods indicated:

	Three Months Ended
	March 31,
	2023			2022
Net Sales		100.0	%		100.0	%
Cost of Goods Sold		84.3			86.8
Gross Profit		15.7			13.2
Selling Expenses		2.6			2.7
General and Administrative Expenses		9.3			8.9
Research and Development Expenses		0.8			1.1
Gain on Sale of Property and Equipment		0.0			(0.1	)
Income from Operations		3.0			0.6
Interest Expense		(0.3	)		(0.3	)
Income Before Income Taxes		2.7			0.3
Income Tax (Benefit) Expense		0.7			(0.2	)
Net Income		2.0	%		0.5	%

20

Net Sales

Net sales were $34.9 million in the first quarter of 2023, as compared to $30.7 million in the first quarter of the prior year, an increase of $4.2 million or 13.7% that was driven primarily due to higher production volume as well as price increases to counteract higher material and labor cost.

Net sales by our major industry markets for the three months ended March 31, 2023 and 2022 were as follows (in millions):

	Three months Ended March 31,
	2023		2022		% Change
Medical	$	21.4	$	15.2		40.8
Industrial		9.5		8.7		9.2
Aerospace and Defense		4.0		6.8		(41.2	)
Total Net Sales	$	34.9	$	30.7		13.7

Net sales by timing of transfer of goods and services for the three ended March 31, 2023 is as follows (in millions):

	Three Months Ended March 31, 2023
	Product/ Service Transferred Over Time		Product Transferred at Point in Time		Noncash Consideration		Total Net Sales by Market
Medical	$	15.7	$	5.1	$	0.6	$	21.4
Industrial		6.6		2.4		0.5		9.5
Aerospace and Defense		3.4		0.5		0.1		4.0
Total net sales	$	25.7	$	8.0	$	1.2	$	34.9

Net sales by timing of transfer of goods and services for the three ended March 31, 2022 is as follows (in millions):

	Three Months Ended March 31, 2022
	Product/ Service Transferred Over Time		Product Transferred at Point in Time		Noncash Consideration		Total Net Sales by Market
Medical	$	9.8	$	4.9	$	0.5	$	15.2
Industrial		6.5		1.8		0.4		8.7
Aerospace and Defense		6.1		0.4		0.3		6.8
Total net sales	$	22.4	$	7.1	$	1.2	$	30.7

21

Backlog

Our 90-day shipment backlog as of March 31, 2023 was $33.8 million, a 5.8% decrease from the beginning of the quarter and a 4.5% decrease from March 31, 2022. Our backlog consists of firm purchase orders we expect to ship in the next 90 days, with any remaining amounts to be shipped within 180 days.

Our 90-day order backlog by market has remained relatively constant when compared to the same period of the prior year. 90-day backlog varies due to order size, manufacturing delays, contract terms and conditions and timing from customer delivery schedules and releases. These variables cause inconsistencies in comparing the backlog from one period to the next.

90-day shipment backlog by our major industry markets are as follows (in millions):

	90 Day Backlog as of the Period Ended
	March 31,		December 31,		March 31,
	2023		2022		2022
Medical	$	20.6	$	21.7	$	19.7
Industrial		7.8		9.1		9.7
Aerospace and Defense		5.4		5.1		6.0
Total 90-Day Backlog	$	33.8	$	35.9	$	35.4

Our total order backlog as of March 31, 2023 was $98.8 million, a 5.1% decrease from $104.1 million at December 31, 2022. Our total backlog remains strong, however customers are returning to their pre-pandemic ordering practices as the global supply chain improves.

Total order backlog by our major industry markets are as follows (in millions):

	Total Backlog as of the Period Ended
	March 31,		December 31,		March 31,
	2023		2022		2022
Medical	$	49.8	$	57.1	$	58.5
Industrial		20.5		22.5		19.1
Aerospace and Defense		28.5		24.5		20.0
Total 90-Day Backlog	$	98.8	$	104.1	$	97.6

The 90-day and total backlog at March 31, 2023 contain the contract asset value of $10.8 million which has been recognized as revenue.

Gross Profit

Gross profit as a percent of net sales was 15.7% and 13.2% for the three months ended March 31, 2023 and 2022, respectively. The gross profit improvement relates primarily to price increases in response to material and labor cost inflation and higher production volume which increased plant utilization.

22

Selling Expense

Selling expenses for the three months ended March 31, 2023 and 2022 was $0.9 million or 2.6% of sales and $0.8 million or 2.7% of sales, respectively.

General and Administrative Expense

General and administrative expenses for the three months ended March 31, 2023 and 2022 were $3.3 million or 9.3% of sales and $2.7 million or 8.9% of sales, respectively. The increase in general and administrative expense was mainly due to higher professional fees and higher cost of labor.

Research and Development Expense

Research and development expenses were $0.3 million for both the three months ended March 31, 2023 and 2022.

Income From Operations

Income from operations was $1.1 million and $0.2 million for the three months ended March 31, 2023 and 2022, respectively. The increase in income from operations was driven by the increase in sales and gross margin as a percent of sales, primarily due to price increases in response to material and labor cost inflation.

Interest Expense

Interest expense was $110 thousand and $98 thousand for the three months ended March 31, 2023 and 2022, respectively. The increase in interest expense relates to increased interest rates on the line of credit in the first quarter of 2023 compared to the first quarter of 2022.

Income Taxes

On a quarterly basis, we estimate what our effective tax rate will be for the full fiscal year and record a quarterly income tax provision based on the anticipated rate. As the year progresses, we refine our estimate based on the facts and circumstances, including discrete events, by each tax jurisdiction. Our effective tax rate for the three months ended March 31, 2023 and 2022 was 28% and (94)%, respectively. The primary drivers of the change in the effective tax rate relates to an increase in the valuation allowance on US deferred tax assets and taxes on foreign entities.The prior year income tax benefit was attributable to the US loss compared to book income on foreign entities and expected US book income for the year.

Net Income

Net income for the three months ended March 31, 2023 was $681 thousand or $0.25 per basic common share and $0.23 per diluted common share. Net income for the three months ended March 31, 2022 was $138 thousand or $0.05 per basic and diluted common share. The increase in net income was driven by the increase in sales and gross margin as a percent of sales, primarily due to price increases in response to material and labor cost inflation.

Liquidity and Capital Resources

We believe that our existing financing arrangements, anticipated cash flows from operations, funds expected to be received for the ERC and cash on hand will be sufficient to satisfy our working capital needs for the next twelve months, capital expenditures and debt repayments.

23

Credit Facility

We have a credit agreement with Bank of America, which was entered into on June 15, 2017 and provides for a line of credit arrangement of $16,000 that expires on June 15, 2026.

Under the amended Bank of America credit agreement signed December 31, 2021, the line of credit is subject to variations in the Bloomberg Short-Term Bank Yield (BSBY) index rate. Our line of credit bears interest at a weighted-average interest rate of 7.3% and 5.2% as of March 31, 2023 and December 31, 2022, respectively. We had borrowings on our line of credit of $5.9 million and $6.9 million outstanding as of March 31, 2023 and December 31, 2022, respectively. There are no subjective acceleration clauses under the credit agreement that would accelerate the maturity of our outstanding borrowings. The line of credit is shown net of debt issuance costs of $41 thousand and $44 thousand on the consolidated balance sheet for the periods ended March 31, 2023 and December 31, 2022, respectively.

The line of credit with Bank of America contains certain covenants which, among other things, require us to adhere to regular reporting requirements, abide by annual shareholder dividend limitations, maintain certain financial performance, and limit the amount of annual capital expenditures.

The Bank of America Credit Agreement provides for, among other things, a Fixed Charge Coverage Ratio of not less than 1.0 to 1.0, for the twelve months ending December 31, 2020 and each Fiscal Quarter end thereafter subject only during a trigger period commencing when our availability under our line is less than $2.0 million until availability is above that amount for 30 days. The Company met the covenants for the period ended March 31, 2023.

At March 31, 2023, we had unused availability under our line of credit of $5.9 million supported by our borrowing base. The line is secured by substantially all of our assets.

Off-Balance Sheet Arrangements

We have not engaged in any off-balance sheet activities as defined in Item 303(a)(4) of Regulation S-K.

Critical Accounting Policies and Estimates

Our significant accounting policies and estimates are summarized in Management’s Discussion and Analysis of Financial Condition and Results of Operations in our Annual Report on Form 10-K for the year ended December 31, 2022. Some of our accounting policies require us to exercise significant judgment in selecting the appropriate assumptions for calculating financial estimates. Such judgments are subject to an inherent degree of uncertainty. These judgments are based on our historical experience, known trends in our industry, terms of existing contracts and other information from outside sources, as appropriate. Actual results could differ from these estimates.

24

Forward-Looking Statements

Those statements in the foregoing report that are not historical facts are forward-looking statements made pursuant to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995.

♦ Volatility in the marketplace which may affect market supply, demand of our products or currency exchange rates;

♦ Supply chain disruption and unreliability;

♦ Lack of supply of sufficient human resources to produce our products;

♦ Increased competition from within the EMS industry or the decision of OEMs to cease or limit outsourcing;

♦ Changes in the reliability and efficiency of our operating facilities or those of third parties;

♦ Increases in certain raw material costs such as copper and oil;

♦ Commodity and energy cost instability;

♦ Risks related to FDA noncompliance;

♦ The loss of a major customer;

♦ General economic, financial and business conditions that could affect our financial condition and results of operations;

♦ Increased or unanticipated costs related to compliance with securities and environmental regulation;

♦ Disruption of global or local information management systems due to natural disaster or cyber-security incident;

♦ Outbreaks of epidemic, pandemic, or contagious diseases, such as the recent novel coronavirus that affect our operations, our customers' operations or our suppliers' operations.

The factors identified above are believed to be important factors (but not necessarily all of the important factors) that could cause actual results to differ materially from those expressed in any forward-looking statement made by us. Discussion of these factors is also incorporated in Part I, Item 1A, “Risk Factors,” and should be considered an integral part of Part II, Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations.” Unpredictable or unknown factors not discussed herein could also have material adverse effects on forward-looking statements. All forward-looking statements included in this Form 10-K are expressly qualified in their entirety by the forgoing cautionary statements. We undertake no obligations to update publicly any forward-looking statement (or its associated cautionary language) whether as a result of new information or future events.

Please refer to forward-looking statements and risks as previously disclosed in our Annual Report on Form 10-K for the fiscal year ended December 31, 2022.

25

ITEM 3.   QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Not applicable.

ITEM 4.   CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

In accordance with Rule 13a-15(b) of the Securities Exchange Act of 1934 (the “Exchange Act”), as of the end of the period covered by this Quarterly Report on Form 10-Q, our management evaluated, with the participation of our Chief Executive Officer and Chief Financial Officer, the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rule 13a-15(e) and Rule 15d-15(e) under the Exchange Act). These controls and procedures are designed to ensure that information required to be disclosed in the Company’s Exchange Act reports is (1) recorded, processed, summarized and reported in a timely manner, and (2) accumulated and communicated to management, including the Company’s Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. Based upon their evaluation of these disclosure controls and procedures as of the date of the evaluation, the Chief Executive Officer and Chief Financial Officer concluded that the disclosure controls and procedures were effective.

Changes in Internal Control Over Financial Reporting

There was no change in our internal control over financial reporting during our most recently completed fiscal quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

26

PART II

ITEM 1.   LEGAL PROCEEDINGS

We are subject to various legal proceedings and claims that arise in the ordinary course of business.

ITEM 1A. RISK FACTORS

We are affected by the risks specific to us as well as factors that affect all businesses operating in a global market. The significant factors known to us that could materially adversely affect our business, financial condition or operating results or could cause our actual results to differ materially from our expectations are described in our annual report on Form 10-K for the fiscal year ended under the heading “Part I – Item 1A.Risk Factors.” There have been no material changes in the risk factors from those disclosed in the Annual Report on Form 10-K for the year ended December 31, 2022.

ITEM 2.   UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

As of March 31, 2023, our share repurchase program has expired, and no additional amounts are available for repurchase.

ITEM 3.   DEFAULTS ON SENIOR SECURITIES

None.

ITEM 4.   MINE SAFETY DISCLOSURES

Not applicable.

ITEM 5.   OTHER INFORMATION

None.

27

ITEM 6. EXHIBITS

Exhibits

31.1*	Certification of the Chief Executive Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a), promulgated under the Securities Exchange Act of 1934, as amended.
31.2*	Certification of the Chief Financial Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a), promulgated under the Securities Exchange Act of 1934, as amended.
32*	Certification of the Chief Executive Officer and Chief Financial Officer, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101*	Financial statements from the quarterly report on Form 10-Q for the quarter ended March 31, 2023, formatted in XBRL: (i) Condensed Consolidated Balance Sheets, (ii) Condensed Consolidated Statements of Operations and Comprehensive Loss, (iii) Condensed Consolidated Statements of Cash Flows, and (iv) the Condensed Notes to Condensed Consolidated Financial Statements.
104	Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).

*Filed herewith

28

Signatures

---------------

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Nortech Systems Incorporated and Subsidiaries

------------------------------------------------------------

Date: May 10, 2023	by /s/ Jay D. Miller
	Jay D. Miller
	Chief Executive Officer and President
	Nortech Systems Incorporated
Date: May 10, 2023	by /s/ Christopher D. Jones
	Christopher D. Jones
	Vice President and Chief Financial Officer
	Nortech Systems Incorporated

29